Crossing from Analytical to Diagnostics: The Difficulty is the Moat

Most analytical technologies never reach clinical diagnostics—not due to inadequate performance, but because clinical markets demand structural transformation: from flexibility to constraint, standardization and manufacturer accountability. The crossing requires seven simultaneous conditions across three phases. This structural distance is not a barrier to avoid but the moat that protects valuable positions. Success requires treating diagnostics as a different operating system, not an adjacent market channel.

Published March 2026
Miguel Oliveira
IVD Industry Monograph No. 1 — Persodia Research

Why does this matter now?

Analytical technologies continue to advance rapidly, and the economic attraction of clinical diagnostics is evident.

Yet most technologies developed for analytical markets never make the crossing into sustained clinical use.

The difficulty is often misunderstood.

Clinical deployment is not simply an adjacent product launch or a regulatory extension. It requires a transformation from one type of system into another: from flexibility and adaptable workflows towards constraint, standardisation and manufacturer accountability for every result in every deployment.

Understanding that structural distance is essential for technology companies, investors and potential partners assessing whether a crossing should be attempted.

The central problem

Almost every clinical measurement principle used in hospitals today originated in analytical science.

The organisations that built the diagnostics industry were not necessarily the organisations that developed those principles. They were the organisations that understood what it takes to deploy them in a clinical setting.

Most analytical technologies never make that crossing.

The reason is not necessarily inadequate performance. Analytical systems and clinical systems are built for different markets.

Analytical systems are designed to maximise flexibility: broad applications, rapid iteration and adaptable workflows.

Clinical environments demand the opposite: constraint, standardisation and manufacturer accountability for every result in every deployment.

This is not a compatibility problem that engineering can resolve alone. It is a structural gap between two types of market, each with its own logic, capital requirements and criteria for what constitutes a functioning product.

The crossing is not a product launch.

It is a transformation from one type of system into another: complete, irreversible and on the clinical market’s terms.

What this monograph examines

The crossing is structured around seven conditions across three phases. They must be met simultaneously. None is sufficient alone.

The monograph examines:

• the structural gap between analytical and diagnostics markets;
• the capital asymmetry of the crossing and its implications for timing and commitment;
• regulatory states as strategic positions, not merely compliance milestones;
• field observations from Analytica Munich 2026 across five technology domains;
• three detailed failure cases and one crossing completed successfully;
• the conditions under which a crossing should not be attempted.

The difficulty is the moat

The barriers that make clinical diagnostics difficult to enter are not incidental to the opportunity.

They are part of what makes a durable position valuable.

A company that treats diagnostics as an adjacent market may underestimate the depth of transformation required. A company that understands the crossing as a structural transition can make a more disciplined decision: whether to commit fully, partner appropriately or decline to enter.

The difficulty is not a reason to avoid the market automatically.

It is the moat.

Analytical basis

The monograph draws on the structural framework developed in Inside the Clinical Diagnostics Industry: Constraints Shaping Strategy — Towards Health Intelligence and on field observation at Analytica Munich 2026.

It is the first publication in the IVD Industry Monograph series: the primary analytical output of Persodia Research.

Strategic implications

Analytical companies should evaluate clinical diagnostics as a different operating system, not as a neighbouring commercial channel.

Executives need to assess whether the organisation is prepared to absorb the full institutional and capital implications of the crossing. Partial commitment is not a lower-risk route. It often creates stranded investment without producing a clinically deployable system.

Investors should distinguish between technically attractive opportunities and structurally complete crossing strategies.

Potential partners should assess where the missing capabilities sit: regulatory ownership, clinical evidence, workflow standardisation, installed-base support, market access, service infrastructure or capital endurance.

The crossing can succeed. But it succeeds only when it is treated as a transformation rather than an extension.

Related Persodia material

Book
Inside the Clinical Diagnostics Industry: Constraints Shaping Strategy — Towards Health Intelligence

Related monographs
Earning Position: How Evidence Becomes Authority
Beyond Market Access: Foundations for Sustaining Europe’s IVD Leadership

Frameworks
The seven crossing conditions
The three-phase crossing model
Regulatory states as strategic positions

About the series

Each monograph in the IVD Industry Monograph series examines a single structural question at the intersection of industry organisation, clinical deployment and market economics.

The series is observational rather than prescriptive, cumulative rather than episodic.

Assumed knowledge

The monograph assumes familiarity with the diagnostics and analytical-instruments industries.

Readers without direct commercial or technical experience in either market will find the structural argument accessible but will benefit from prior reading of Inside the Clinical Diagnostics Industry.

Access

This monograph is available without charge.

Access requires a brief declaration of context and intended use. Persodia Research wishes to understand who engages with the material and in what professional context.

Full copyright is retained by the author. The material may be read, cited and discussed freely. It may not be reproduced or repurposed without prior written permission.

Request Automatic Download